WO2021103982A1 - Timbre dégradable pour le traitement d'anévrisme et système d'orientation de sang - Google Patents

Timbre dégradable pour le traitement d'anévrisme et système d'orientation de sang Download PDF

Info

Publication number
WO2021103982A1
WO2021103982A1 PCT/CN2020/126989 CN2020126989W WO2021103982A1 WO 2021103982 A1 WO2021103982 A1 WO 2021103982A1 CN 2020126989 W CN2020126989 W CN 2020126989W WO 2021103982 A1 WO2021103982 A1 WO 2021103982A1
Authority
WO
WIPO (PCT)
Prior art keywords
patch
degradable
balloon
wire
porous
Prior art date
Application number
PCT/CN2020/126989
Other languages
English (en)
Chinese (zh)
Inventor
张海军
侯文博
李建文
周文秀
王燕
房艺
Original Assignee
张海军
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 张海军 filed Critical 张海军
Publication of WO2021103982A1 publication Critical patent/WO2021103982A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/958—Inflatable balloons for placing stents or stent-grafts

Definitions

  • the invention relates to a degradable patch and a blood flow guiding system for treating aneurysms, belonging to the field of interventional medical devices.
  • Vascular aneurysm is due to the disease or injury of the arterial wall, which forms the performance of localized or diffuse expansion or bulging of the arterial wall, with swelling and pulsating masses as the main manifestations.
  • Aneurysms can occur in any part of the arterial system, depending on where the aneurysm appears, including cerebral aneurysms, visceral aneurysms, peripheral aneurysms, abdominal aortic aneurysms, etc.
  • Interventional therapy is currently an important means of treating aneurysms.
  • a commonly used method is to implant releasable balloons, coils and other embolic materials into the aneurysm body through a catheter, so that the blood flow in the tumor body is significantly slowed down or stagnated, and gradually Thrombus is formed to block the tumor body, thereby achieving the purpose of preventing the rupture of the aneurysm.
  • the above-mentioned interventional embolization therapy has obvious defects in the treatment of large (diameter greater than 10mm) or huge (diameter greater than 25mm) aneurysms: because the effect of coils in the treatment of aneurysms is related to the degree of dense embolization, this The surgeon is required to place as many coils as possible during the operation. Therefore, in the treatment of wide-necked and giant aneurysms, coil embolization will cause more obvious gravity and space-occupying effects, and the recurrence rate after surgery is also very high. high.
  • a new intracranial aneurysm treatment device came into being, that is, the blood flow guide device.
  • a blood flow guiding device also known as a dense mesh stent
  • the mechanism of the blood flow guiding device is that it interferes with the blood flow from the tumor-bearing artery into the aneurysm, causing the blood in the aneurysm to block and stagnate, leading to thrombosis in the aneurysm, and further promoting its complete closure.
  • the current blood flow guide devices on the market are mainly Pipeline Embolization Device (Covedien/ev3), Silk stent (Balt Extrusion), Tubridge (MicroPort Shentong Medical Technology (Shanghai) Co., Ltd.), etc.
  • the Pipeline is braided by 32 metal wires with a metal coverage rate of 30% to 35%.
  • the delivery method consists of a delivery guide wire and a matching 3F microcatheter. At present, more than 2,600 patients have been treated by Pipeline.
  • Silk stent is the first blood flow guiding device approved for clinical treatment. It is composed of 48 nickel-titanium alloys, and its metal coverage is 35%-50%. Its delivery method is also a guide wire and a supporting microcatheter. The micro-catheter has the function of re-recovering the stent. When the release of the stent does not exceed 80%, the stent can be re-recovered into the catheter, thereby realizing the movement and relocation of the stent.
  • the Tubridge device is a domestic dense mesh stent jointly developed by MicroPort Shentong Medical Technology (Shanghai) Co., Ltd. and Shanghai Changhai Hospital. Its composition and principle are roughly the same as the first two, with a mesh rate of 60%-80%. It is transported in the Tubridge device. During the process, the metal coverage at the neck of the aneurysm can be increased to 30%-70% through the cooperation of the guide wire and the microcatheter, while the metal coverage at other locations is only 12%-20%.
  • the adherence, shortening rate, and influence on the blood flow of branch vessels after the implantation of the vascular guide device are important indicators to ensure its effectiveness.
  • the purpose of the present invention is to provide a degradable patch for the treatment of aneurysms, the patch is made of degradable materials, the degradation process and products will not cause damage to the human body, high safety, and the patch The wall is good, which can effectively reduce the phenomenon of device displacement, and will not affect the blood flow of branch vessels while occluding the aneurysm.
  • a degradable patch for treating aneurysms that is, a blood flow guiding device, comprises a patch body and an adhesive located at the edge of the patch body, the patch body is made of degradable materials.
  • the section of the patch body is arched, the radius is 2.0-10mm, the central angle is 45°-270°, the length of the patch body is 5-50mm, and the thickness of the patch body is 0.05-1mm.
  • the patch body is not closed in the circumferential direction and does not cover the branch blood vessels, so the blood flow of the branch blood vessels will not be affected while the aneurysm is occluded.
  • the patch body is a non-porous solid structure or a porous structure.
  • the porosity of the porous patch body is 10%-70%.
  • the non-porous solid patch body is made of a biodegradable material through a plate molding method or an injection molding method.
  • the degradable material used here is preferably a polymer degradable material, which can be prepared by the existing flat plate molding method or injection molding method, and the molding is simple.
  • porous patch body is woven from a filamentous degradable material, or is obtained by forming holes in a non-porous solid patch body.
  • the filamentous degradable material is a degradable metal alloy wire, such as zinc alloy wire, magnesium alloy wire, iron alloy wire or other degradable metal alloy wire, etc., or may be a polymer biodegradable wire, such as Polylactic acid-based biodegradable silk, starch-based biodegradable silk, etc.
  • This filamentous degradable material can be maintained in the body for months or years, and the degradation process and products will not cause harm to the human body.
  • the diameter of metal alloy wire or polymer biodegradable wire is 0.025-0.5mm.
  • the weaving method of the filamentous degradable material can be carried out with reference to the methods disclosed in the prior art, and the size, thickness, shape, porosity, etc. of the weaving can be adjusted according to actual needs.
  • the patch body when the patch body is woven from a filamentous degradable material, the patch body has a relatively high weaving coverage, which can reach 30%-90%. At this time, the sum of braid coverage and porosity is 100%.
  • the method of forming holes on the non-porous solid patch body can be carried out by the methods disclosed in the prior art.
  • the non-porous solid patch body is made first, and then the solid patch body is formed by mechanical means. Pores are formed on the body; or, when preparing the non-porous solid patch body, a certain proportion of porogen is added to the raw material (the porogen particles can be water-soluble inorganic salts such as sodium chloride, sodium tartrate and sodium citrate, or Sugar particles, paraffin particles or ice particles can also be used.
  • the non-porous solid patch body is made by plate molding or injection molding, and then the porogen is precipitated by the precipitation method to obtain a porous patch body.
  • an adhesive is provided on the patch body, and the adhesive is located on one surface of the patch body and located at the peripheral edge of the patch body.
  • the adhesive is a soft, biologically compatible double-sided tape, which can form a tough bond between the wet blood vessel wall and the patch body, and has good wall adhesion.
  • the present invention also provides a blood flow guiding system for treating aneurysms, the blood flow guiding system comprising a delivery system and the above-mentioned degradable patch for treating aneurysms.
  • the delivery system includes a puncture kit, a balloon guiding catheter and a balloon delivery catheter, and the degradable patch for treating aneurysms is located on the outer wall of the balloon of the balloon delivery catheter.
  • the balloon guiding catheter and the balloon delivery catheter are used together to deliver the degradable patch to the desired location.
  • the puncture kit includes a puncture needle, a micro-guide wire, a catheter sheath, and a dilator.
  • the degradable patch is pressed on the outer wall of the balloon of the balloon delivery catheter, and the biocompatible adhesive is coated on the periphery of the degradable patch.
  • the degradable patch is delivered to the aneurysm through interventional methods, and the expansion After the balloon, the neck of the aneurysm is fully covered, which can effectively reduce the blood flowing into the aneurysm.
  • the degradable patch of the present invention has good adhesion to the wall, can effectively reduce the phenomenon of device displacement, and will not affect the blood flow of branch vessels while occluding the aneurysm.
  • the degradable patch of the present invention is bonded to the inner wall of the blood vessel with a biocompatible adhesive, which can achieve good adhesion and can avoid the phenomenon of device displacement after implantation;
  • the degradable patch of the present invention does not close in the circumferential direction and does not cover the branch blood vessels, so it will not affect the blood flow of the branch blood vessels while occluding the aneurysm.
  • the overall volume of the degradable patch of the present invention is small, the occupancy rate in the blood vessel is reduced, the restenosis in the blood vessel and the formation of intravascular thrombus can be effectively reduced, and it is more safe and reliable.
  • Figure 1 is a schematic diagram of the structure of a woven degradable patch.
  • Figure 2 is a schematic diagram of the structure of a non-porous material-type degradable patch.
  • Figure 3 is a schematic diagram of the structure of a porous material-type degradable patch.
  • Figure 4 is a cross-sectional view of a degradable patch with a central angle of 90°.
  • Figure 5 is a cross-sectional view of a degradable patch with a central angle of 120°.
  • Figure 6 is a cross-sectional view of a degradable patch with a central angle of 180°.
  • Figure 7 is a cross-sectional view of a degradable patch with a central angle of 270°.
  • Figure 8 is a diagram of the placement position of the degradable patch (an axial cut view of the tumor-bearing blood vessel).
  • Fig. 9 is a diagram of the placement position of the degradable patch (a sectional view of the axis of the tumor-bearing blood vessel).
  • Fig. 10 is a schematic diagram of the structure of a balloon guiding catheter and a balloon delivery catheter.
  • Fig. 11 is a schematic diagram of the structure of the balloon delivery catheter after being placed in the balloon guiding catheter.
  • FIG. 12 is a schematic diagram of the structure of a balloon fixed with a degradable patch.
  • Figure 13 is a schematic diagram of the degradable patch transportation process.
  • the degradable patch 100 of the present invention is composed of a patch body 110 and a biocompatible adhesive 120.
  • the adhesive is located on the peripheral edges of the patch body, and is only located on the patch body.
  • the patch body is made of degradable material.
  • the patch body is not closed in the circumferential direction, the section is arched, the radius is 2.0-10mm, the central angle is 45°-270°, the length is 5-50mm, and the thickness is 0.05-1mm.
  • the patch body 110 may have a porous structure.
  • the patch body may be woven from a filamentous degradable material, and the filamentous degradable material used may be a metal alloy wire or a polymer.
  • Biodegradable wire such as zinc alloy, magnesium alloy, iron alloy, etc.
  • polymer biodegradable wire such as polylactic acid, starch-based, etc.
  • the diameter of the filamentous degradable material is 0.025-0.5mm, and the degradable filament begins to degrade after being implanted in the body for 3 months to 3 years.
  • the patch body 110 can be woven with a 48-, 64-, 72-, or 144-spindle medical precision knitting machine, with a knitting density of 70-200 PPI.
  • the woven patch body has a higher woven coverage, which can reach 30%-90%, and the porosity is 10%-70%.
  • the patch body 110 may also be a solid structure. As shown in FIG. 2, the patch body 110 may also be made of a non-porous material.
  • the non-porous material may be made of silica gel, polylactic acid and other polymers. It is made of degradable materials, and the preparation method can be made by flat plate molding or injection molding process.
  • the patch body 110 may also be a porous structure as shown in FIG. 3, and the porous structure may be improved on the basis of the non-porous structure shown in FIG. 2, for example, the non-porous structure shown in FIG. Pore structure, and then further pore-forming treatment to obtain a porous structure, or when preparing the above-mentioned non-porous structure, a certain proportion of porogen is added to the raw material, and then the porogen is precipitated by the precipitation method to obtain a porous structure.
  • the pore size and porosity of the porous structure can be adjusted by selecting the particle size and content of the porogen, and the porosity is 10%-40%.
  • Figures 4-7 are cross-sectional views of the degradable patch 100, showing different specifications in the circumferential direction of the patch.
  • the degradable patch 100 is not closed in the circumferential direction, and such an unclosed design can effectively avoid affecting the blood flow of branch vessels.
  • the central angle ⁇ ranges from 45° to 270°.
  • the radius r of the degradable patch can be determined according to the diameter R of the tumor-bearing blood vessel, and the range is 2.0-10.0mm.
  • the degradable patch 100 should cover at least the neck of the aneurysm and extend 5-10 mm to both sides. Therefore, the specification selection of the degradable patch can be summarized as the following formula:
  • r is the radius in the circumferential direction
  • R is the diameter of the tumor-bearing vessel
  • L is the length in the axial direction
  • L' is the length of the aneurysm neck
  • ⁇ is the central angle in the circumferential direction.
  • the length of the degradable patch is generally 5-50mm.
  • the adhesive 120 is a soft, biocompatible double-sided tape that is evenly and evenly adhered to the periphery of the degradable patch 100.
  • the adhesive 120 can be Absorb the moisture on the surface of the wet tissue within seconds, and at the same time form the cross-linking of physical bonds and covalent bonds with the tissue, strongly bond various soft and wet tissues in the body and implanted equipment, and maintain high bonding strength, high flexibility, and high biology for a long time. Compatibility, final biodegradation, and it needs to be ensured that the adhesive 120 starts to degrade at least 1-3 days longer than the degradable patch 100.
  • FIGS. 10-12 show schematic structural diagrams of a blood flow guiding system for treating aneurysm, which includes a balloon delivery system 300 and the above-mentioned degradable patch 100.
  • the degradable patch 100 is inserted into a designated position through the delivery system 300.
  • the balloon delivery system 300 includes a balloon delivery catheter 310, a balloon guiding catheter 320, and a conventional puncture kit, which includes a puncture needle, a micro-guide wire, a catheter sheath, and a dilator.
  • the A channel of the balloon guiding catheter 320 is an inflation channel, and the balloon 321 can be expanded to a certain extent by a pressure pump.
  • the B channel is the assembly channel of the balloon delivery catheter 310.
  • the C channel of the balloon delivery catheter 310 is an inflation channel, and the degradable patch 100 is attached to the inner wall of the tumor-bearing blood vessel by expanding the balloon 311.
  • the D channel is the channel of the micro-guide wire.
  • the balloon delivery catheter 310 also includes a balloon 311, and the visualization line 312 is located on one side of the balloon 311.
  • the visualization material may be a visualization material commonly used in medical treatment, such as barium sulfate, bismuth, or tungsten.
  • the assembly process is as follows: the degradable patch 100 is first fixed on the outer wall of the balloon delivery catheter 310 by a crimping device, and the degradable patch is installed on the outer wall of the balloon 311 symmetrically with respect to the development line 312, as shown in FIG. 12 . Then penetrate the distal end of the balloon guide catheter 320 and pass through the reserved holes of the internal fixation frames 322 and 323 to ensure the coaxiality of the balloon delivery catheter 310 and the balloon guide catheter 320, as shown in

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Surgical Instruments (AREA)
  • Prostheses (AREA)

Abstract

La présente invention se rapporte au domaine des instruments médicaux. L'invention concerne un timbre dégradable (100) pour traiter un anévrisme, et un système d'orientation de sang. Le timbre dégradable (100) comprend un corps principal de timbre (110) et un adhésif (120) positionné au niveau d'un bord du corps principal de timbre (110). Le corps principal de timbre (110) est constitué d'un matériau dégradable. Le timbre dégradable (100) a une apposition de paroi favorable, peut empêcher efficacement un instrument de se déplacer, et n'affecte pas l'écoulement de sang dans un vaisseau ramifié tout en permettant l'occlusion d'un anévrisme.
PCT/CN2020/126989 2019-11-27 2020-11-06 Timbre dégradable pour le traitement d'anévrisme et système d'orientation de sang WO2021103982A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911180103.X 2019-11-27
CN201911180103.XA CN110934661B (zh) 2019-11-27 2019-11-27 一种用于治疗动脉瘤的可降解贴片及其输送方法

Publications (1)

Publication Number Publication Date
WO2021103982A1 true WO2021103982A1 (fr) 2021-06-03

Family

ID=69908538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/126989 WO2021103982A1 (fr) 2019-11-27 2020-11-06 Timbre dégradable pour le traitement d'anévrisme et système d'orientation de sang

Country Status (2)

Country Link
CN (1) CN110934661B (fr)
WO (1) WO2021103982A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110934661B (zh) * 2019-11-27 2023-01-03 张海军 一种用于治疗动脉瘤的可降解贴片及其输送方法
CN115040300A (zh) * 2021-03-09 2022-09-13 常州至善医疗科技有限公司 一种体内植入物的封闭和释放结构
CN113331990B (zh) * 2021-04-22 2023-04-07 中国人民解放军空军军医大学 载药型弹性可降解人工血管及其构建方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1556689A (zh) * 2001-07-20 2004-12-22 ���ŷ� 动脉瘤治疗装置
WO2006099111A2 (fr) * 2005-03-12 2006-09-21 Starfire Medical, Inc. Reducteurs d'anevrismes
CN101282697A (zh) * 2004-01-22 2008-10-08 微排放器公司 动脉瘤治疗装置
CN102188300A (zh) * 2010-03-02 2011-09-21 微创医疗器械(上海)有限公司 一种动脉瘤手术装置
CN207429131U (zh) * 2016-12-16 2018-06-01 上海形状记忆合金材料有限公司 一种冠状动脉瘘封堵器
WO2019175288A1 (fr) * 2018-03-13 2019-09-19 Institut Químic De Sarrià Cets Fundació Privada Timbre de réparation vasculaire
CN110934661A (zh) * 2019-11-27 2020-03-31 张海军 一种用于治疗动脉瘤的可降解贴片及其输送方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803574B2 (en) * 2003-05-05 2010-09-28 Nanosys, Inc. Medical device applications of nanostructured surfaces
CN102824198B (zh) * 2011-06-13 2016-03-30 上海市第六人民医院 一种可/直接粘贴血管覆膜
CN105498074B (zh) * 2015-12-25 2017-08-08 李雷 血管壁修复系统

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1556689A (zh) * 2001-07-20 2004-12-22 ���ŷ� 动脉瘤治疗装置
CN101282697A (zh) * 2004-01-22 2008-10-08 微排放器公司 动脉瘤治疗装置
WO2006099111A2 (fr) * 2005-03-12 2006-09-21 Starfire Medical, Inc. Reducteurs d'anevrismes
CN102188300A (zh) * 2010-03-02 2011-09-21 微创医疗器械(上海)有限公司 一种动脉瘤手术装置
CN207429131U (zh) * 2016-12-16 2018-06-01 上海形状记忆合金材料有限公司 一种冠状动脉瘘封堵器
WO2019175288A1 (fr) * 2018-03-13 2019-09-19 Institut Químic De Sarrià Cets Fundació Privada Timbre de réparation vasculaire
CN110934661A (zh) * 2019-11-27 2020-03-31 张海军 一种用于治疗动脉瘤的可降解贴片及其输送方法

Also Published As

Publication number Publication date
CN110934661B (zh) 2023-01-03
CN110934661A (zh) 2020-03-31

Similar Documents

Publication Publication Date Title
WO2021103982A1 (fr) Timbre dégradable pour le traitement d'anévrisme et système d'orientation de sang
US11685007B2 (en) Devices, systems, and methods for treatment of intracranial aneurysms
US6689148B2 (en) Methods and apparatus for intraluminal deposition of hydrogels
ES2391763T3 (es) Dispositivo de embolización
EP2543345B1 (fr) Instrument chirurgical pour les anévrismes
JP4794781B2 (ja) 発泡体基質の塞栓形成装置および塞栓形成システム
JP4990625B2 (ja) 塞栓組成物
US20120172911A1 (en) Occlusion device
US20160331380A1 (en) Embolic device, an apparatus for embolizing a target vascular site and a method thereof
CN111920558A (zh) 一种颅内动脉瘤血流导向支架
WO2013056497A1 (fr) Nécessaire pour dispositif de type implant intravasculaire et procédé de fabrication dudit dispositif de type implant
US20150238195A1 (en) Methods and systems for performing intralumenal procedures
US20130046326A1 (en) Methods and systems for performing intralumenal procedures
CN106859723B (zh) 一种血管内介入医学用体内可降解弹簧圈
CN112274204B (zh) 医用弹簧圈
CN109925018B (zh) 瘤内栓塞用串联封堵链段及采用其的动脉瘤封堵系统
WO2004069058A1 (fr) Dispositif pour l'obturation de vaisseaux sanguins
CN215079203U (zh) 医疗植入物
WO2024005748A1 (fr) Cathéter à endoprothèse à ballonnet doté d'une pointe occluse
CN115089255A (zh) 一种生物可降解医用弹簧圈及其应用
CN118203381A (zh) 封堵系统及封堵装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20893040

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20893040

Country of ref document: EP

Kind code of ref document: A1